Virological efficacy in HIV-infected patients affected by non-Hodgkin lymphoma, treated with antiblastic chemotherapy and highly active antiretroviral therapy

Scandinavian Journal of Infectious Diseases, Supplement

Volumn , Issue 106, 2003, Pages 49-53

  Simonelli, Cecilia ^a   Zanussi, Stefania ^a   Cinelli, Roberta ^a   Dal Maso, Luigino ^a   Di Gennaro, Giampiero ^a   D'Andrea, Monica ^a   Nasti, Guglielmo ^a   Spina, Michele ^a   Vaccher, Emanuela ^a   De Paoli, Paolo ^a   Tirelli, Umberto ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; CD20 ANTIBODY; CD4 ANTIGEN; CD8 ANTIGEN; CYCLOPHOSPHAMIDE; CYTOCHROME P450 3A; DIDANOSINE; DOXORUBICIN; ETOPOSIDE; GLYCOPROTEIN P; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PACLITAXEL; PREDNISONE; PROTEINASE INHIBITOR; RITONAVIR; RITUXIMAB; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TAXANE DERIVATIVE; UNINDEXED DRUG; VINBLASTINE; VINCA ALKALOID; VINCRISTINE; ZALCITABINE; ZIDOVUDINE; VIRUS RNA;

ADULT; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG ACCUMULATION; DRUG EFFICACY; DRUG METABOLISM; FEMALE; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; NEUROTOXICITY; NONHODGKIN LYMPHOMA; VIRUS MUTATION; VIRUS REPLICATION; VIRUS RESISTANCE; ANTIBIOTIC RESISTANCE; COMPARATIVE STUDY; DRUG COMBINATION; DRUG EFFECT; DRUG INTERACTION; EPIDEMIOLOGY; GENETICS; METHODOLOGY; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDY; RISK ASSESSMENT; SURVIVAL; TREATMENT OUTCOME; VIRUS LOAD;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG INTERACTIONS; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HIV INFECTIONS; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RNA, VIRAL; SAMPLING STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VIRAL LOAD; VIRUS REPLICATION;

EID: 1242342143     PISSN: 03008878     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Palella Jr FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338: 853-60.
2. Detels R, Munoz A, McFarlane G, Kingsley LA, Margolick JB, Giorgi J, et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. JAMA 1998; 280: 1497-503.
3. Mocroft A, Vella S, Benfield TL, Chiesi A, Miller V, Gargalianos P. et al. Changing patterns of mortality across Europe in patients infected with HIV-1. Euro-SIDA Study Group. Lancet 1998; 352: 1725-30.
4. Hogg RS, Heath KV, Yip B, Craib KJ, O'Shaughnessy MV, Schechter MT, Montaner JS. Improved survival among HIV infected individuals following initiation of antiretroviral therapy. JAMA 1998; 6: 450-4.
5. Jones JL, Hanson DL, Dworkin MS, Ward JW, Jaffe HW. Adult/Adolescent Spectrum of HIV Disease Project Group. Effect of antiretroviral therapy on recent trends in selected cancers among HIV-infected persons. J Acquir Immun Defic Syndr 1999; 21 (Suppl 1): 11-7.
6. Jacobson LP, Yamashita TE, Detels R, Margolick JB, Chmiel JS, Kingsley LA, et al. Impact of potent antiretroviral therapy on the incidence of Kaposi's sarcoma and non-Hodgkin's lymphoma among HIV-1 infected individuals. J Acquir Immun Defic Syndr Hum Retrovirol 1999; 21 (Suppl 1): 34-41.
7. Ledergerber B, Telenti A, Egger M, for the Swiss Cohort Study. Risk of HIV related Kaposi's sarcoma and non-Hodgkin's lymphoma with potent antiretroviral therapy: prospective cohort study. Br Med J 1999; 319: 23-4.
8. Ledergerber B, Egger M, Erard V, Weber R, Hirschel B, Furrer H, et al. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy JAMA 1999; 282: 2220-6.
9. International Collaboration on HIV and Cancer. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J Natl Cancer Inst 2000; 92: 1823-9.
10. Bower M, Fox P, Fife K, Gill J, Nelson M, Gazzard B. Highly active anti-retroviral therapy (HAART) prolongs time to treatment failure in Kaposi's sarcoma. AIDS 1999; 13: 2105-11.
11. Dal Maso L, Serraino D, Franceschi S. Epidemiology of AIDS-related tumours in developed and developing countries. Eur J Cancer 2001; 37: 1188-201.
12. Matthews GV, Bower M, Mandalia S, Powles T, Nelson MR, Gazzard BG. Changes in acquired immunodeficiency syndrome-related lymphoma since the introduction of highly active antiretroviral therapy. Blood 2000; 96: 2730-4.
13. Thiessard F, Morlat P, Marimoutou C, Labouyrie E, Ragnaud JM, Pellegrin JL, et al. Prognostic factors after non-Hodgkin's lymphoma in patients infected with the human immunodeficiency virus. Cancer 2000; 88: 1696-702.
14. Conti S, Masocco M, Pezzotti P, Toccaceli V, Vichi M, Boros S, et al. Differential impact of combined antiretroviral therapy on the survival of Italian patients with specific AIDS-defining illnesses. J Acquir Immun Defic Syndr 2000; 25: 451-8.
15. Romeu J, Navarro T, Tural C, Sirera G, Ribera JM, Clotet B. Effect of HAART on response to therapy and survival in patients with AIDS-related non-Hodgkin's lymphoma (NHL). Programme and Abstracts of the XIII International AIDS Conference, 9 14 July 2000, Durban, South Africa. Abstract TuOrB303.
16. Kirk O, Pedersen C, Cozzi-Lepri A, Antunes F, Miller V, Gatell JM, et al., for the EuroSIDA Study Group. Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy. Blood 2001; 98: 3406-12.
17. Gates AE, Kaplan LD. AIDS malignancies in the era of highly active antiretroviral therapy. Oncology (Huntingt) 2002; 16: 441-51.
18. Zanussi S, Simonelli C, D'Andrea M, Comar M, Bidoli E, Giacca M, et al. The effects of antineoplastic chemotherapy on HIV disease. AIDS Res Hum Retrovirol 1996; 12: 1703-7.
19. Powles T, Imami N, Nelson M, Gazzard BG, Bower M. Effects of combination chemotherapy and highly active antiretroviral therapy on immune parameters in HIV-1 associated lymphoma. AIDS 2002; 16: 531-6.
20. Mackall CL, Fleisher TA, Brown MR, Magrath IT, Shad AT, Horowitz ME, et al. Lymphocyte depletion during treatment with intensive chemotherapy for cancer. Blood 1994; 84: 2221-8.
21. + suppressor-inducer T-cells. Cancer Res 1988; 48: 1671-5.
22. Mouton Y, Alfandari S, Valette M, Cartier F, Dellamonica P, Humbert G, et al. Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres. AIDS 1997; 11: 101-5.
23. Flexner C. HIV-protease inhibitors. N Engl J Med 1998; 338: 1281-92.
24. Rowinsky EK, Donehower RC. Pharmacology of cancer chemotherapy-antimicrotubule agents. In: De Vita VT, Hellman S, Rosenberg SA, eds. Cancer principles and practice of oncology, 5th edn.. Philadelphia: Lippincott-Raven; 1997. p. 467-83.
25. Washington CB, Duran GE, Man MC, Sikic BI, Blaschke TF. Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells. J AIDS Hum Retrovirol 1998; 19: 203-9.
26. Fischer G, Lum B, Sikic BI. Clinical studies with modulators of multidrug resistance. In: Fischer G, Sikic B, eds. Drug resistance in clinical oncology and hematology. Philadelphia: WB Saunders; 1995. p. 363-82.
27. Vaccher E, Spina M, di Gennaro G, Talamini R, Nasti G, Schioppa O, et al. Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma. Cancer 2001; 91: 155-63.
28. Levine AM. Acquired immunodeficiency syndrome-related lymphoma: clinical aspects. Semin Oncol 2000; 27: 442-53.
29. Tam HK, Zhang ZF, Jacobson LP, Margolick JB, Chmiel JS, Rinaldo C, Detels R. Effect of highly active antiretroviral therapy on survival among HIV-infected men with Kaposi sarcoma or non-Hodgkin lymphoma. Int J Cancer 2002; 98: 916-22.
30. Gatti G, De Pascalis CR, Toffoli G, Di Gennaro G, Milerich F, Bassetti M, et al. Pharmacokinetic interaction between indinavir and CHOP (adryamicin, cyclophosphamide, vincristin) (Abstract). Pharmacotherapy 2001; 21 (Suppl): 3775, 119.
31. Gatti G, De Pascalis CR, Toffoli G, Di Gennaro G, Milerich F, Bassetti M, et al. Case control study of indinavir pharmacokinetics in patients undergoing chemotherapy for AIDS related neoplasia (Abstract). 2nd International Workshop on Clinical Pharmacology of HIV Therapy, Noordwijk, The Netherlands, 2001.
32. Ratner L, Lee J, Tang S, Redden D, Hamzeh F, Herndier B, et al. Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy. J Clin Oncol 2001; 19: 2171-8.
33. Toffoli G, Tolusso B, Vaccher E, Corona G, Bernardi D, Boiocchi M, Tirelli U. Saquinavir and antineoplastic chemotherapy interactions in in-vitro human cancer cell lines and in HIV-associated non-Hodgkin's lymphoma (HIV-NHL) patients (Abstract). Proc ASCO 2001; 20: 101b, 2153.
34. Little RF, Pearson D, Gutierrez M, Steinberg S, Yarchoan R, Wilson WH. Dose-adjusted EPOCH chemotherapy in previously untreated HIV-associated non-Hodgkin's lymphoma (Abstract). Proc Am Soc Clin Oncol 1999; 18: 10a.